SCHEMBL10097495

SCHEMBL10097495

CCCn1c(-c2ccc(NC(=O)NC(C)CC)cc2)c(N)c2ccc(OC)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.47
PKM P14618 1/20 0.43
RAB9A P51151 3/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 2/20 0.41
ADORA2B P29275 3/20 0.41
ADORA2A P29274 2/20 0.41
FPR2 P25090 1/20 0.40
ADORA1 P30542 1/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ANPEP P15144 1/20 0.37
NPC1 O15118 2/20 0.37
TP53 P04637 1/20 0.37
MAPK1 P28482 1/20 0.37
STAT1 P42224 1/20 0.37
HSD17B10 Q99714 1/20 0.37
NAMPT P43490 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13151937 0.93 PKM (0.42) ALDH1A1PKMRAB9AADORA2BADORA2A
SCHEMBL10252376 0.87 CNR2 (0.41) ALDH1A1PKMADORA2BADORA2ASMN1; SMN2
SCHEMBL13153261 0.87 MTNR1B (0.49) RAB9AADORA2BADORA2AADORA1SMN1; SMN2
SCHEMBL10096403 0.87 ALDH1A1 (0.44) ALDH1A1PKMRAB9ACA12CA1
SCHEMBL13152142 0.86 ADORA2B (0.41) RAB9AADORA2BADORA2AADORA1NPC1
SCHEMBL13152223 0.85 NPC1 (0.50) ALDH1A1RAB9AADORA2BADORA2AMAPT
SCHEMBL10097816 0.84 ALDH1A1 (0.45) ALDH1A1MAPTSMN1; SMN2TP53MAPK1
SCHEMBL10254338 0.84 PKM (0.44) ALDH1A1PKMRAB9AMAPTSMN1; SMN2
SCHEMBL10250706 0.83 MTNR1B (0.47) ALDH1A1RAB9AADORA2BADORA2ANPC1
SCHEMBL10097284 0.82 NPC1 (0.47) ALDH1A1PKMRAB9ACA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations PTC THERAPEUTICS, INC. (US) 2012-02-02 US disclosed
WO-2007084435-A2 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2007-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120027721-A1 HCV Inhibitor and Therapeutic Agent Combinations HAVCR2, SERPINB1, ENPEP ALDH1A1 1067/4885PKM 4485/4885RAB9A 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.